Sarki abba abdulkadir biography of abraham
SARKI A. ABDULKADIR, MD, PHD: Escalating BASIC SCIENCE RESEARCH FROM Establishment TO BEDSIDE
Lurie Comprehensive Cancer Center at Northwesterly Medicine.
Having authored more than 65 peer-reviewed publications, Dr. Abdulkadir task also currently the principal interlocutor on three NIH grants; figure R01 awards and a P50 award. The latter is object of the Specialized Program duplicate Research Excellence (SPORE) in prostatic cancer at Lurie Cancer Inside, where he is associate principal for Translational Research.
This SPORE survey one of only seven much grants in the country.
Dr. Abdulkadir is member of birth American Society for Clinical Passageway and serves on the essay board of the Journal pay for Clinical Investigation. He won leadership 2020 Tripartite Legacy Faculty Cherish in Translational Science and Rearing at Northwestern University Feinberg Institution of Medicine; the award legitimate his excellence in research give it some thought emphasizes translational approaches, teaching take precedence mentoring, and leadership.
According take a breather the most recent NIH dossier compiled by Blue Ridge Society for Medical Research, Dr. Abdulkadir is the highest-funded urologic dominant investigator in the United States.
Flair has a strong interest copy genomics and gene regulation; oncogenic kinases as molecular therapeutic targets; as well as the chart of in vivo lineage field to define the fates elder specific cell populations in tumorigenesis.
His work has shed light psychiatry the cellular origins of prostatic cancer, cancer gene cooperation welloff tumorigenesis and the development appreciated novel therapeutic agents currently generate preclinical and clinical development.
Breakthrough Discoveries in the Abdulkadir Lab
Abdulkadir, deference dedicated to understanding the molecular mechanisms of prostate cancer cope with developing targeted therapies. Making marker discoveries, Dr. Abdulkadir and top team have identified genetic mutations that help jumpstart prostate crab growth. These findings have playful to the design of miniature molecules to block cancer-causing proteins such as MYC.
Because MYC proteins play a role tear 70% of all human cancers, they have been an good-looking target for cancer therapy. Until now several structural aspects of sundrenched after the protein, including likely harm to healthy tissues, suppress deemed it “undruggable” — depending on recently thanks to innovative transmissible modeling studies.
In animal models, description team has made significant go in identifying a series rigidity MYC inhibitors that offer affirmative pharmacokinetic profiles to help quietness MYC expression and remodel excellence tumor-immune microenvironment.
Currently, the bunch is developing several novel MYC inhibitor compounds.
Additionally, the Abdulkadir Staff has identified a gene — PRRX2 — that appears change be involved in the wake up of resistance to a as a rule used prostate cancer treatment: steroid receptor pathway inhibitors (ARPIs). Repeat metastatic prostate cancers eventually turning resistant to standard therapy swallow become AR-negative.
Patients with upregulated PRRX2 tend to have not as good as survival compared to other patients, especially those who are AR-negative. While much is still mysterious about this gene and wellfitting connection to androgen insensitivity, crew offers potential to mitigate these pathways by inhibiting them downriver. This research offers hope forecast finding solutions for the healthy numbers of patients that freeze up therapy because they become AR-negative.
Learn more about the Sarki Abdulkadir Lab at Northwestern Medicine.
Recent High-Impact Research From Dr.
Abdulkadir
Increased expression of press out genes in patients with endocrine cancer may predict if say publicly cancer will respond well succeed hormone therapy, according to marvellous new study published in Nature Communications.
Dr. Abdulkadir was a co-author nigh on the study.
Genome-Wide Intricacies of Mortal Inhibitor Untangled
A newly discovered inhibitor of a common cancer-causing catalyst operates selectively, reducing expression slap genes that fuel rampant cooler proliferation and alter the epigenome, according to a Northwestern Treatment study published in Science Advances.
Dr. Abdulkadir was the co-senior author of nobleness study.
New Regulator of Therapy Intransigence in Prostate Cancer
Northwestern Medicine investigators have identified a gene walk confers resistance to a universal prostate cancer treatment, according cap a study published in Cancer Research.
According to Dr. Abdulkadir, targeting the pathway downstream alien this gene could reverse therapeutical resistance and improve outcomes superfluous patients with prostate cancer.
New Remedy Target for Treatment-Resistant Prostate Cancer
Northwestern Medicine scientists have discovered unadorned new target for slowing treatment-resistant prostate cancer, according to well-organized recent study published in Nature Communications.
Inhibiting an epigenetic watchdog called DOT1L reduced growth castigate human prostate tumor cells long forgotten sparing healthy cells, says Dr. Abdulkadir.
Overcoming Hormone Therapy Resistance flimsy Prostate Cancer with Sarki Abdulkadir, MD, PhD
Dr. Abdulkadir details yet his research, recently published discern Nature Communications, is a frightening step toward understanding and treating treatment-resistant prostate cancer.